Weight and See: The Use and Impact of GLP-1 RAs in Obesity and Long-Term Disease Management

Obesity is a serious, chronic, and progressive disease involving genetic, biological, and environmental influences. Obesity is a worldwide epidemic that impacts more than just a person’s weight. Obesity is associated with over 200 different organ complications affecting every organ system in the body. People with obesity lose years of life due to the disease and obesity-related complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide benefit in overcoming the mechanisms of obesity leading to significant weight loss, and also provide benefit combatting many of the mechanisms of obesity-associated comorbidities such as prediabetes, type 2 diabetes, metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, osteoarthritis, and heart failure with preserved ejection fraction. Additionally, GLP-1 RAs have shown benefit in the reduction of major adverse cardiovascular events, atherosclerotic cardiovascular disease (ASCVD) risk reduction, various benefits throughout the body, and a reduction in morbidity and mortality in patients with obesity.

Given the serious impact of obesity and its related comorbidities, adherence to obesity medications and treating comorbidities is crucial for improving patient outcomes. Pharmacists can provide long-term, patient-centered care and positively impact patient outcomes. Pharmacists are the most accessible healthcare professionals who play a key role in obesity management, treating obesity-related comorbidities, and providing patient education on the importance of long-term disease management for reducing the risk of morbidity and mortality.

Wednesday, April 23
1 - 2 p.m. ET

Registration is required for this webinar.